Categories
Articles Medicinal Science

Contemporary advances in therapeutic portfolio of 2-Azetidinones

urn:nbn:sciencein.cbl.2020v7.98

Contemporary advances in therapeutic portfolio of 2-Azetidinones

  • Rajneesh Kaur Maharishi Markandeshwar (Deemed to be University)
  • Dr. (Mrs.) Raman Singh Maharishi Markandeshwar (Deemed to be University)
  • Priyanka Ahlawat Maharishi Markandeshwar (Deemed to be University)
  • Parul Kaushik Maharishi Markandeshwar (Deemed to be University)
  • Kuldeep Singh Maharishi Markandeshwar University

Keywords: β-lactams, monobactam, antimicrobial drug resistance, biological activity, multi target drugs

Abstract

The heterocycle moieties form the site of reaction in many enzymes and co-enzymes and also act as an important pharmacophore in the pharmaceutical drug designs. 2-Azetidinones are the 2-carbonyl derivatives of azetidine, more commonly known as ?-lactams. These structural entities occupied a central role in the vigil against bacterial infections over the past few decades. A subclass of these heterocyclic systems, monobactams or monocyclic ?-lactam derivatives exhibits several biological activities including antibacterial, antifungal, antiprotozoal, anti-mycobacterial, anti-HIV, antiviral, antimalarial, antioxidant, apoptotic inhibitors, anti-inflammatory activity, anticancer activity, herbicidal activity, etc. Monobactams has resistant to the ?-lactamase enzyme and could be a reasonable starting point for developing new drugs or inhibitors. In the present review, pharmacological activities of monocyclic ?-lactam derivatives have been discussed with respect to current research in the structure-activity relationships in different therapeutic areas.

beta lactams in medicinal research

Cite as: K. Rajneesh, R. Singh, P. Ahlawat, P. Kaushik, K. Singh. Contemporary advances in therapeutic portfolio of 2-Azetidinones. Chem. Biol. Lett. 2020, 7 (1), 13–26.

Full text http://thesciencein.org/journal/index.php/cbl/article/view/98